The American Journal of Human Genetics, Volume 109

# **Supplemental information**

# Rescue of a familial dysautonomia mouse

## model by AAV9-Exon-specific U1 snRNA

Giulia Romano, Federico Riccardi, Erica Bussani, Simone Vodret, Danilo Licastro, Isabella Ragone, Giuseppe Ronzitti, Elisabetta Morini, Susan A. Slaugenhaupt, and Franco Pagani

# Supplemental Information

# Supplemental Methods

Primer list

mIkbkap	For	5'-TGATTGACACAGACTCTGGCCA-3'
(genotyping)	Rev	5'-CTTTCACTCTGAAATTACAGGAA-3'
hIkbkap	For	5'-GCCATTGTACTGTTTGCGACT-3'
(genotyping)	Rev	5'-TGAGTGTCACGATTCTTTCTGC-3'
hELP1	For	5'-GGCCGGCCTGAGCAGCAATCATGTGTCC-3'
	Rev	5'GATTCTCAGCTTTCTCATGCATTC-3'
ExSpeU1-FD	For	5'-ATAGCAAACAGTACAATGC-3'
	Rev	5'-CACTACCACAAATTATGCA-3'
U1	For	5'-ATACTTACCTGGCAGGGGGGGAGAT-3'
	Rev	5'-GGAAAGCGCGAACGCAGTCCCCCAC-3'
mGAPDH	For	5'-ATGGTGAAGGTCGGTGTGAA-3'
	Rev	5'-GTTGATGGCAACAATCTCCA-3'

# Supplemental Figures

Body Weight • control \* control treated • FD • FD-treated  $n_{s}$   $n_{s}$  $n_{s}$  n

# Figure S1. Measurements of body weights in FD mice and littermate controls treated with AAV9-U1-FD or saline only.

Weekly measurements were reported in the graph as mean  $\pm$ SD; color code: littermate controls + saline in black; littermate controls + AAV9-U1-FD in gray; FD + saline in orange; FD-treated with AAV9-U1-FD in blue. ns=not significant, \*\*\* *p*<0.00. *n*>15 mice for each group.

А

#### в Gels - PND-10 Gels - PND-90 FD FD-treated FD FD-treated 19 20 21 --------19 21 Brain 15.3 18.7 15.2 15.6 21.8 40.9 48.9 40.1 31.3 25.2 20.2 14.9 13.2 18.2 20.8 29.3 42.6 43.5 39.4 19 20 21 19 21 DRG . 21.2 21.3 15.4 16.2 22.8 58.6 69.6 69.3 54.2 56.3 22.9 15.4 19.1 19.6 36.5 33.4 34.2 36.9 24.2 19 20 21 19 21 -20.8 35.0 21.4 20.0 59.1 69.1 31.9 19.1 62.7 ΤG 18.1 30.0 19 20 21 19 21 SCG 22.7 29.4 20.3 60.8 70.0 65.6 19 20 21 19 21 SC 22.5 25.2 20.8 21.3 24.7 39.6 37.2 27.8 24.7 28.9 33.2 25.3 19 20 21 \_ 19 21 41.5 43.3 59.1 66.2 50.0 57.2 63.8 98.0 100 100 91.3 94.3 Liver 46.9 19 20 21 \_\_\_\_ 19 21 54.1 Heart 57.1 56.1 55.3 51.3 59.6 83.3 89.4 86.9 76.5 79.1 63.0 65.3 59.5 61.5 71.8 70.0 19 20 21 -19 21 39.5 44.5 38.6 38.2 43.1 66.4 78.0 73.1 46.0 51.8 Muscle 41.2 30.1 36.3 19 20 21 19 21 43.2 30.5 33.5 47.4 54.0 67.8 56.0 41.6 42.3 38.5 33.9 Lung 32.8 39.6 38.5 38.2 43.1 19 20 21 19 21 36.8 49.5 50.7 61.7 94.3 37.9 41.2 37.7 41.0 45.9 41.0 46.6 Kidney 55.1 48.7 19 20 21 19 21 Eye 58.6 62.9 60.2 61.8 65.8 68.7 71.0 72.3 64.3 64.5 62.3 60.4 61.4 61.3 60.8 64.5 63.8 55.8 60.8 70.6

\_\_\_\_ 24.6 26.4 24.2 29.4 34.6 33.4 35.3 30.6 45.7 55.1 51.1 46.3 37.1 \_\_\_\_\_ 73.9 67.3 \_\_\_\_ 37.9 45.3 52.6 44.0 32.3 33.7 23.9 26.1 45.1 40.9 53.9 50.8 35.8 40.3

19 20 21

19 20 21

19 20 21

19 20 21

19 20 21

19 20 21

19 20 21

19 20 21

19 20 21

19 20 21

19 20 21

19 21

19 21

19 21

19 21

19 21

19 21

19 21

19 21

19 21

19 21

19 21

30.5

36.7

41.4

60.1

35.5

----

С





Figure S2. Tissue specific *ELP1* splicing rescue in FD mice.

(A-B) Agarose gels of *ELP1* splicing isoforms in FD animals (*Ikbkap*<sup>420</sup>/*Ikbkap*<sup>flox</sup>; h-TgFD9/+) treated with saline and AAV9-U1-FD at PND-10 and PND-90 respectively in (A) and in (B). The upper band of 202 bp represents the *ELP1* isoform in which exon 20 is included, whereas the lower band of 128 bp represents the isoform in which exon 20 is skipped. DRG=dorsal root ganglia; TG= trigeminal ganglia; SCG=superior cervical ganglia; SC=spinal cord. The percentage of exon 20 inclusion is reported below each lane, for all tissues the 5 analyzed animals are shown (except for SCG and TG in which 3 animals per group were tested). (C) qPCR quantification of ExSpeU1-FD in FD animals treated with saline and AAV9-U1-FD at PND-10 and PND-90. Expression levels were normalized on *Gapdh* and one FD-treated PND-10 mouse was set to 1. ns=not significant, \*\*\* *p*<0.001 and \*\**p*<0.01. Data are expressed as mean±SEM of two technical replicates on 4 mice per group.



Figure S3. AAV9-U1-FD treatment rescues protein levels in FD mice.

(A-G) Western blot membranes probed with anti-Ikap and anti-GAPDH in different tissues of control mice at PND-10 (*Ikbkapflox/*+; h-TgFD9/+; lanes 1 and 2), FD (*Ikbkap<sup>420</sup>/Ikbkap<sup>flox</sup>*; h-TgFD9/+; lanes 3-5 at PND-10 and lanes 9-11 at PND-90) and FD-treated (*Ikbkap<sup>420</sup>/Ikbkap<sup>flox</sup>*; h-TgFD9/+; lanes 6-8 at PND-10 and lanes 12-14 at PND-90). 3 mice for each group were tested, except for trigeminal ganglia group in which 2 animals were analyzed: (C) control mice at PND-10 lanes 1 and 2, FD + saline lanes 3-4 at PND-10 and lanes 7-8 at PND-90 and FD-treated lanes 5-6 at PND-10 and lanes 9-10 at PND-90.



## Figure S4. AAV9-U1-FD treatment in FD mice rescues some of the pathological traits of FD.

Several tests and analyses were performed on littermate controls (*Ikbkap*<sup>flox/+</sup>; h-TgFD9/+) and FD mice (*Ikbkap*<sup>A20</sup>/*Ikbkap*<sup>flox</sup>; h-TgFD9/+) treated with one intracerebral ventricular injection (ICV) at PND-0 and a second intraperitoneal injection (IP) at PND-2 of AAV9-U1-FD (1.6 x  $10^{11}$  VG/mouse) or saline only. Littermate controls + saline in black; FD + saline in orange; FD-treated with AAV9-U1-FD in blue. (A) Gait assay pattern. A representative footprint pattern is shown for each group, fore paws are stained in blue and hind paws are stained in red. (B) Rotarod test in control and FD mice (*n*=10 per group) at 1,2, 3 and 4 months. (C) Hanging test in control and FD mice (*n*=10

per group) at 2 months. Statistical analysis was performed using one-way ANOVA with Bonferroni correction. Values reported in (B and C) are means ± SEM. ns=not significant.

Group	Alternative Splicing Events	n of Analyzed Events Σ Σ mean counts ≥20 (SE-MXE-RI)		Significant Different Events -0.2 ≤ Inclusion Level Difference ≥0.2 FDR≲0.05		
		≥40 (A5SS-A3SS)	%	n tot	down/up	
	SE	101,518	0.05%	51	26/25	
ExSpeU1-FD vs Empty	MXE	37,465	0.5%	197	105/92	
	RI	2,604	0.2%	5	1/4	
	A5SS	2,757	0.04%	1	0/1	
	A3SS	4,039	0.05%	2	1/1	

Figure S5. Summary table of alternative splicing analysis in HEK-293 Flp-In T-REx stable clone overexpressing ExSpeU1-FD.

The total number of analyzed events and the percentage of the significant ones are reported for each category (SE=skipped exon; MXE=mutually exclusive exon; RI=retained intron; A5SS=alternative 5' splice site; A3SS=alternative 3' splice site). Total number of analyzed events = sum ( $\Sigma$ ) of the counts means  $\geq$  20 (SE-MXE-RI) or  $\geq$  40 (A5SS-A3SS). Significant events: FDR  $\leq$  0.05 and Inclusion Level Difference  $\leq$  -0.2 or  $\geq$  0.2.



Figure S6. Expression and alternative splicing events in dorsal root ganglia in FD mice.

(A-C) Non-quantitative Venn diagram showing the significantly differentially expressed genes (A), skipped exons (B) and mutually exclusive exons (C) shared across FD vs WT (red circle), T vs WT (blue circle) and T vs FD (green circle) comparisons at PND-10. Common genes are labeled in orange to indicate events that go in the same direction or in violet to indicate those that go in the opposite direction. (D-L) Volcano plots showing global alternative splicing

changes in (D-F) retained introns (RI), (G-I) alternative 5' splice sites (A5SS) and (J-L) alternative 3' splice sites (A3SS) at PND-10. In panels (D), (G) and (J) FD mice are compared to WT mice (FD vs WT); in panels (E), (H) and (K) FD-treated mice are compared to WT (T vs WT); in panels (F), (I) and (L) FD-treated mice are compared to FD mice (T vs FD). Horizontal blue line (FDR  $\leq 0.05$ ) and vertical red lines (Inclusion Level Difference  $\leq -0.2$  or  $\geq 0.2$ ) indicate cut-off values and determine significant events in each category.

Figure S7

Group	Alternative Splicing Events	n of Analyzed Events Σ mean counts ≥20 (SE-MXE-RI)	Significant Different Events -0.2 ≤ Inclusion Level Difference ≥0.2 FDR≤0.05		
		240 (A355-A355)	%	n tot	down/up
	SE	48,783	0.15%	73	45/28
	MXE	8,890	0.60%	53	30/23
FD VS WI	RI	3,171	0.50%	17	15/2
	A5SS	2,246	0.13%	3	3/0
	A3SS	3,740	0.13%	8	5/3
	SE	43,708	0.21%	91	55/36
	MXE	7,615	0.81%	62	31/31
T vs WT	RI	3,171	0.82%	33	26/7
	A5SS	2,087	0.38%	10	8/2
	A3SS	3,470	0.20%	7	7/0
	SE	47,804	0.07%	35	18/17
	MXE	8,672	0.06%	8	5/3
I VS FD	RI	3,233	0.12%	7	4/3
	A5SS	2,198	0.09%	4	2/2
	A3SS	3,634	0.03%	1	1/0

## Figure S7. Summary table of alternative splicing analysis in dorsal root ganglia in FD mice.

The total number of analyzed events and the percentage of the significant ones are reported in each group (FD vs WT, T vs WT and T vs FD) for each category (SE=skipped exon; MXE=mutually exclusive exon; RI=retained intron; A5SS=alternative 5' splice site; A3SS=alternative 3' splice site). Total number of analyzed events = sum ( $\Sigma$ ) of the counts means  $\geq 20$  (SE-MXE-RI) or  $\geq 40$  (A5SS-A3SS). Significant events: FDR  $\leq 0.05$  and Inclusion Level Difference  $\leq -0.2$  or  $\geq 0.2$ .



### Figure S8. Gene expression analysis in a different FD model.

Volcano plots showing differential gene expression changes in the FD model published by *Goffena et al.*, 2018<sup>1</sup>, in which there is a selective ablation of the *ELP1* gene in DRG. In this mouse *Ikbkap* is deleted from the neural crest resulting in embryonic lethality and dorsal root ganglia were analyzed at E17-18, comparing *Ikbkap\_WT* (*Ikbkap+/LoxP*) versus *Ikbkap\_KO* (*Wnt1-Cre; Ikbkap<sup>LoxP/LoxP</sup>*). Transcriptome data deposited at Gene Expression Omnibus, accession number GSE80130. The horizontal blue line (padj  $\leq$  0.05, corresponding to a -log<sub>10</sub> =1.3) and vertical red lines (log<sub>2</sub>FoldChange  $\leq$  -1 or  $\geq$  1) indicate cut-off values. Only three genes are significant differentially expressed with these cut-off values.

## **Supplemental Tables**

**Table S1. RNA-seq analysis in HEK Flp-In T-Rex cell line, ExSpeU1-FD versus control.** Summary (sheet1); list of the significant candidates of the differential gene expression (sheet 2) and Ingenuity Pathway analysis (sheet 3). Alternative splicing events analysis (Skipped Exon, sheet 4; Retained Intron, sheet 5; Mutually Exclusive Exons, sheet 6; Alternative 5' splice site, sheet 7; Alternative 3' splice site, sheet 8) in HEK293 Flp-In-T-Rex cell line. ExSpeU1-FD vs control clones.

**Table S2. RNA-seq analysis in DRG of PND-10 mice.** Summary (sheet 1); list of the significant candidates of the differential gene expression in dorsal root ganglia of FD mice vs control (WT) (sheet 2), treated (T) vs WT (sheet 3) and T vs FD (sheet 4). Ingenuity Pathway analysis on DGE of FD vs WT (sheet 5) and T vs WT (sheet 6). Mice at PND 10.

**Table S3. List of the significant alternative splicing events in dorsal root ganglia of FD mice vs control (WT) at PND-10.** Summary, sheet 1; Skipped Exon, sheet 2; Retained Intron, sheet 3; Mutually Exclusive Exons, sheet 4; Alternative 5' splice site, sheet 5; Alternative 3' splice site, sheet 6.

Table S4. List of the significant alternative splicing events in dorsal root ganglia of treated (T) mice vs control (WT) at PND-10. Summary, sheet 1; Skipped Exon, sheet 2; Retained Intron, sheet 3; Mutually Exclusive Exons, sheet 4; Alternative 5' splice site, sheet 5; Alternative 3' splice site, sheet 6.

Table S5. List of the significant alternative splicing events in dorsal root ganglia of treated (T) mice vs FD at **PND-10.** Summary, sheet 1; Skipped Exon, sheet 2; Retained Intron, sheet 3; Mutually Exclusive Exons, sheet 4; Alternative 5' splice site, sheet 5; Alternative 3' splice site, sheet 6.

## **Supplemental References**

1. Goffena, J., Lefcort, F., Zhang, Y., Lehrmann, E., Chaverra, M., Felig, J., Walters, J., Buksch, R., Becker, K.G., and George, L. (2018). Elongator and codon bias regulate protein levels in mammalian peripheral neurons. Nat. Commun. *9*, 1–10.